TY - JOUR
T1 - The immunotherapy era of myeloma
T2 - Monoclonal antibodies, vaccines, and adoptive T-cell therapies
AU - Hoyos, Valentina
AU - Borrello, Ivan
N1 - Publisher Copyright:
© 2016 by The American Society of Hematology.
PY - 2016/9/29
Y1 - 2016/9/29
N2 - The treatment of multiple myeloma has evolved significantly over the last decades from primarily alkylator-based chemotherapeutic agents with minimal efficacy to the introduction of more effective agents including immune modulators and proteasome inhibitors, which have changed the landscape of therapy for this disease. We are now entering a new era that will increasingly integrate immunotherapy into standard treatment. This review discusses the currentimmune-based strategies currently approved, as well as various immune approaches being actively investigated including monoclonal antibodies, checkpoint inhibitors, vaccines, and adoptive T-cell therapies.
AB - The treatment of multiple myeloma has evolved significantly over the last decades from primarily alkylator-based chemotherapeutic agents with minimal efficacy to the introduction of more effective agents including immune modulators and proteasome inhibitors, which have changed the landscape of therapy for this disease. We are now entering a new era that will increasingly integrate immunotherapy into standard treatment. This review discusses the currentimmune-based strategies currently approved, as well as various immune approaches being actively investigated including monoclonal antibodies, checkpoint inhibitors, vaccines, and adoptive T-cell therapies.
UR - http://www.scopus.com/inward/record.url?scp=84990864169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990864169&partnerID=8YFLogxK
U2 - 10.1182/blood-2016-05-636357
DO - 10.1182/blood-2016-05-636357
M3 - Review article
C2 - 27506540
AN - SCOPUS:84990864169
SN - 0006-4971
VL - 128
SP - 1679
EP - 1687
JO - Blood
JF - Blood
IS - 13
ER -